Key result
Antiplatelet therapy is active in secondary stroke prevention, though optimal dosing, combination regimens, and side-effect profiles remain areas of ongoing research.
Why the study?
Does antiplatelet therapy prevent secondary stroke in patients requiring secondary stroke prevention?
Does antiplatelet therapy prevent secondary stroke in patients requiring secondary stroke prevention?
This review summarizes the evidence on monotherapy and combination antiplatelet therapy for secondary stroke prevention, focusing on efficacy, dosing, and side-effect profiles.
Answers are grounded in this paper and cite their sources.
Supports antiplatelet use in secondary stroke prevention; leaves open optimal dosing and regimens for prospective trials.
The precise role of antiplatelet therapy in secondary stroke prevention remains a matter of some debate. Although specific antiplatelet agents (notably aspirin, ticlopidine, dipyridamole, and clopidogrel) have been shown to be active in the prevention of secondary stroke, questions remain about the effective dose of these agents and their potential efficacy in combined therapeutic regimens. In addition, haematological and gastrointestinal side-effects of antiplatelet agents remain a significant clinical concern for patients and prescribing physicians. This review article examines research on both monotherapy and combination antiplatelet therapy for secondary stroke prevention, with an emphasis on lessons learned about dosage schedules, treatment protocols, and side-effect profiles.
No takes yet. Share an insight, caveat, or question.
C.D. Forbes (1999) conducted a review in Secondary stroke prevention. Antiplatelet therapy was evaluated. Antiplatelet therapy is active in secondary stroke prevention, though optimal dosing, combination regimens, and side-effect profiles remain areas of ongoing research.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: